Executive Summary: Valuing a machine learning platform requires more than assessing revenue growth. Buyers and investors also evaluate API call volume, compute cost efficiency, model accuracy benchmarks, and the defensibility created by switching costs. For Chicago business owners, especially those in software, financial services, and industrial technology, these metrics can shift valuation outcomes materially because […]
Executive Summary: Data moats are one of the most important drivers of value in an AI business because they determine whether the company can train stronger models, retain customers, and defend pricing over time. For Chicago business owners, investors, and advisors, proprietary training data, data network effects, and data exclusivity agreements can materially improve valuation […]
Executive Summary: Generative AI startup valuation is driven less by narrative hype and more by measurable economics. Buyers and investors typically focus on annual recurring revenue (ARR), enterprise contract size, model defensibility, gross margin profile, retention quality, and the pace at which competition can compress pricing power. In practice, the strongest valuations often go to […]
Executive Summary: Valuing an AI company requires a different lens than applying a standard software or services multiple. Investors and buyers focus not only on revenue growth, but also on ARR quality, model differentiation, data advantages, compute cost structure, customer retention, and the durability of the competitive moat. For Chicago business owners, understanding how these […]
Executive Summary: Electronic health record (EHR) and health IT software companies are valued differently from traditional service businesses because a meaningful share of their worth comes from recurring revenue quality, retention, and the difficulty customers face when switching systems. Buyers and investors typically focus on annual recurring revenue (ARR), net revenue retention (NRR), implementation stickiness, […]
Executive Summary. Valuing an AI-powered diagnostics company requires more than applying a standard revenue multiple. Buyers and investors focus on the durability of FDA clearance, the quality of clinical validation, the structure of licensing or software revenue, and the company’s ability to scale inside health systems. Companies with credible regulatory traction, recurring revenue, strong gross […]
Executive Summary: Revenue cycle management (RCM) software companies are valued not only on current earnings, but on the quality, durability, and predictability of the revenue they generate. For Chicago business owners, investors, and advisors, the most important valuation drivers typically include revenue per provider, claim success rates, net revenue retention (NRR), customer concentration, and the […]
Telehealth platform valuation depends on more than reported revenue. Buyers and investors look closely at patient visit volume, revenue per visit, payer contract penetration, retention, and whether growth remains durable as post-pandemic demand normalizes. For Chicago business owners, especially those serving regional health systems, employer groups, or specialty practices, understanding how these metrics affect value […]
Healthtech business valuation focuses on how digital health companies create durable revenue, manage clinical and regulatory risk, and turn usage data into measurable economics. For Chicago business owners, investors, and advisors, understanding how valuer teams price these companies is essential because traditional EBITDA analysis often understates the value of fast-growing platforms with recurring subscription revenue, […]
Executive Summary: InsurTech valuations are driven less by headline revenue alone and more by the quality of that revenue, the durability of customer retention, and the economics of insurance underwriting. For Chicago business owners, investors, and advisors evaluating an InsurTech company, key metrics such as loss ratio, combined ratio, premium growth, and retention rates help […]
- 1
- 2